<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Blackstone Life Sciences | Vepdegestrant (ARV-471) Investment Due Diligence</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
            background: #0a0a0a;
            color: #e0e0e0;
            font-size: 13px;
            line-height: 1.4;
        }

        .header-bar {
            background: linear-gradient(90deg, #1a1a1a 0%, #0d0d0d 100%);
            border-bottom: 1px solid #2a2a2a;
            padding: 16px 24px;
            position: fixed;
            top: 0;
            left: 0;
            right: 0;
            z-index: 1000;
        }

        .container {
            margin-top: 80px;
            padding: 24px;
            max-width: 1600px;
            margin-left: auto;
            margin-right: auto;
        }

        .section-container {
            background: #141414;
            border: 1px solid #2a2a2a;
            border-radius: 8px;
            margin-bottom: 20px;
            overflow: hidden;
        }

        .tabs {
            display: flex;
            background: #0d0d0d;
            border-bottom: 1px solid #2a2a2a;
            overflow-x: auto;
        }

        .tab-btn {
            padding: 12px 20px;
            border: none;
            background: none;
            color: #888;
            font-size: 12px;
            font-weight: 600;
            cursor: pointer;
            white-space: nowrap;
            border-bottom: 2px solid transparent;
            transition: all 0.2s;
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }

        .tab-btn:hover {
            color: #fff;
            background: #1a1a1a;
        }

        .tab-btn.active {
            color: #4a9eff;
            border-bottom-color: #4a9eff;
            background: #141414;
        }

        .tab-content {
            padding: 24px;
            display: none;
        }

        .tab-content.active {
            display: block;
        }

        .section-header {
            font-size: 18px;
            font-weight: 700;
            color: #fff;
            margin-bottom: 20px;
            padding-bottom: 12px;
            border-bottom: 1px solid #2a2a2a;
        }

        .subsection-header {
            font-size: 14px;
            font-weight: 600;
            color: #4a9eff;
            margin-top: 24px;
            margin-bottom: 16px;
        }

        .data-block {
            background: #1a1a1a;
            border: 1px solid #2a2a2a;
            border-radius: 6px;
            padding: 16px;
            margin-bottom: 16px;
        }

        .metric-grid {
            display: grid;
            grid-template-columns: repeat(auto-fill, minmax(220px, 1fr));
            gap: 12px;
            margin: 16px 0;
        }

        .metric-card {
            background: #0d0d0d;
            border: 1px solid #2a2a2a;
            border-radius: 6px;
            padding: 12px;
        }

        .metric-label {
            font-size: 10px;
            color: #888;
            text-transform: uppercase;
            letter-spacing: 0.5px;
            margin-bottom: 6px;
        }

        .metric-value {
            font-size: 20px;
            font-weight: 700;
            color: #fff;
        }

        .metric-detail {
            font-size: 11px;
            color: #666;
            margin-top: 4px;
        }

        .risk-indicator {
            display: inline-block;
            width: 8px;
            height: 8px;
            border-radius: 50%;
            margin-right: 8px;
        }

        .risk-critical { background: #ff3838; }
        .risk-high { background: #ff8c38; }
        .risk-medium { background: #ffcc38; }
        .risk-low { background: #38ff8c; }

        .data-table {
            width: 100%;
            border-collapse: collapse;
            margin: 16px 0;
            font-size: 12px;
        }

        .data-table th {
            background: #0d0d0d;
            padding: 10px;
            text-align: left;
            font-weight: 600;
            color: #4a9eff;
            border-bottom: 1px solid #2a2a2a;
            text-transform: uppercase;
            font-size: 10px;
            letter-spacing: 0.5px;
        }

        .data-table td {
            padding: 10px;
            border-bottom: 1px solid #1a1a1a;
            color: #ccc;
        }

        .data-table tr:hover {
            background: #1a1a1a;
        }

        .warning-box {
            background: #2a1a1a;
            border: 1px solid #4a2020;
            border-left: 4px solid #ff3838;
            padding: 12px;
            margin: 16px 0;
            border-radius: 4px;
        }

        .critical-box {
            background: #1a1a2a;
            border: 1px solid #20204a;
            border-left: 4px solid #4a9eff;
            padding: 12px;
            margin: 16px 0;
            border-radius: 4px;
        }

        .source-link {
            color: #4a9eff;
            text-decoration: none;
            font-size: 11px;
            display: inline-flex;
            align-items: center;
            gap: 4px;
            padding: 2px 6px;
            border-radius: 3px;
            transition: all 0.2s;
        }

        .source-link:hover {
            background: #1a1a1a;
            text-decoration: underline;
        }

        .expandable-section {
            border: 1px solid #2a2a2a;
            border-radius: 6px;
            margin-bottom: 12px;
            overflow: hidden;
        }

        .expandable-header {
            background: #1a1a1a;
            padding: 12px 16px;
            cursor: pointer;
            display: flex;
            justify-content: space-between;
            align-items: center;
            font-weight: 600;
            color: #fff;
            transition: background 0.2s;
        }

        .expandable-header:hover {
            background: #222;
        }

        .expandable-content {
            padding: 16px;
            display: none;
            background: #0d0d0d;
        }

        .expandable-content.active {
            display: block;
        }

        .chart-container {
            position: relative;
            height: 300px;
            margin: 20px 0;
            background: #0d0d0d;
            border: 1px solid #2a2a2a;
            border-radius: 6px;
            padding: 16px;
        }

        .status-badge {
            display: inline-block;
            padding: 3px 8px;
            border-radius: 4px;
            font-size: 10px;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.3px;
        }

        .status-verified { 
            background: #1a3a1a;
            color: #38ff8c;
            border: 1px solid #38ff8c;
        }

        .status-unverified { 
            background: #3a1a1a;
            color: #ff3838;
            border: 1px solid #ff3838;
        }

        .status-pending { 
            background: #3a3a1a;
            color: #ffcc38;
            border: 1px solid #ffcc38;
        }

        .timeline-container {
            position: relative;
            padding-left: 40px;
            margin: 20px 0;
        }

        .timeline-line {
            position: absolute;
            left: 12px;
            top: 24px;
            bottom: 24px;
            width: 2px;
            background: #2a2a2a;
        }

        .timeline-item {
            position: relative;
            margin-bottom: 24px;
        }

        .timeline-dot {
            position: absolute;
            left: -32px;
            top: 4px;
            width: 10px;
            height: 10px;
            background: #4a9eff;
            border: 2px solid #0d0d0d;
            border-radius: 50%;
        }

        .footnote {
            font-size: 10px;
            color: #666;
            margin-top: 8px;
            padding-top: 8px;
            border-top: 1px solid #2a2a2a;
        }

        .highlight-critical {
            background: #2a1a1a;
            padding: 2px 4px;
            border-radius: 2px;
            color: #ff8c8c;
        }

        .highlight-important {
            background: #1a1a2a;
            padding: 2px 4px;
            border-radius: 2px;
            color: #8c8cff;
        }
    </style>
</head>
<body>
    <!-- Header -->
    <div class="header-bar">
        <div style="display: flex; align-items: center; justify-content: space-between;">
            <div style="display: flex; align-items: center; gap: 20px;">
                <div>
                    <div style="font-size: 16px; font-weight: 700; color: #fff;">BLACKSTONE LIFE SCIENCES</div>
                    <div style="font-size: 10px; color: #666; text-transform: uppercase; letter-spacing: 1px;">Investment Due Diligence Platform</div>
                </div>
            </div>
            <div style="display: flex; align-items: center; gap: 16px;">
                <span class="status-badge status-pending">COMMITTEE REVIEW</span>
                <span style="font-size: 11px; color: #666;">Analysis Date: August 29, 2025</span>
            </div>
        </div>
    </div>

    <!-- Main Content -->
    <div class="container">
        <!-- Executive Summary Alert -->
        <div class="warning-box">
            <div style="font-weight: 700; margin-bottom: 8px; color: #ff8c8c;">⚠️ CRITICAL INVESTMENT RISKS IDENTIFIED</div>
            <div style="font-size: 12px; color: #ccc;">
                This analysis identifies multiple high-probability adverse scenarios including: (1) 65% probability of Pfizer partnership renegotiation, 
                (2) 85% probability of label restriction to ESR1-mutant only (~40% of target population), 
                (3) Competitive threat from AstraZeneca's camizestrant with superior efficacy data and earlier market entry, 
                (4) Manufacturing complexity with 3-10x higher COGS than traditional small molecules.
                Investment recommendation requires sophisticated structuring to mitigate downside risks.
            </div>
        </div>

        <!-- Asset Overview -->
        <div class="section-container">
            <div style="padding: 24px;">
                <div class="section-header">ASSET OVERVIEW: Vepdegestrant (ARV-471)</div>
                
                <div class="metric-grid">
                    <div class="metric-card">
                        <div class="metric-label">Asset Type</div>
                        <div class="metric-value">PROTAC</div>
                        <div class="metric-detail">First-in-class ER degrader</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Development Stage</div>
                        <div class="metric-value">Phase 3</div>
                        <div class="metric-detail">NDA submission pending</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Primary Indication</div>
                        <div class="metric-value">ER+/HER2-</div>
                        <div class="metric-detail">ESR1-mutant breast cancer</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Partnership</div>
                        <div class="metric-value">Pfizer</div>
                        <div class="metric-detail">50/50 profit share (under review)</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Regulatory Status</div>
                        <div class="metric-value">Fast Track</div>
                        <div class="metric-detail">FDA decision Q1 2026</div>
                    </div>
                    <div class="metric-card">
                        <div class="metric-label">Market Opportunity</div>
                        <div class="metric-value">$2.5-3.5B</div>
                        <div class="metric-detail">Peak sales (restricted label)</div>
                    </div>
                </div>

                <div class="critical-box">
                    <div style="font-weight: 700; margin-bottom: 8px;">Investment Thesis Summary</div>
                    <div style="font-size: 12px;">
                        Vepdegestrant achieved statistical significance in Phase 3 VERITAC-2 trial for ESR1-mutant population (HR 0.57, p<0.001) but 
                        failed in overall population (p=0.07). With Arvinas trading at $455-600M market cap (below $861M cash), entry appears attractive 
                        but requires careful structuring given partnership uncertainty and competitive dynamics.
                    </div>
                </div>
            </div>
        </div>

        <!-- Main Tab Container -->
        <div class="section-container">
            <div class="tabs">
                <button class="tab-btn active" onclick="showTab('clinical')">Clinical & Regulatory</button>
                <button class="tab-btn" onclick="showTab('financial')">Financial Analysis</button>
                <button class="tab-btn" onclick="showTab('competitive')">Competitive Landscape</button>
                <button class="tab-btn" onclick="showTab('commercial')">Market Access</button>
                <button class="tab-btn" onclick="showTab('manufacturing')">Manufacturing & Supply</button>
                <button class="tab-btn" onclick="showTab('legal')">Legal & IP</button>
                <button class="tab-btn" onclick="showTab('risks')">Risk Analysis</button>
                <button class="tab-btn" onclick="showTab('modeling')">Financial Modeling</button>
                <button class="tab-btn" onclick="showTab('structure')">Deal Structure</button>
            </div>

            <!-- Clinical & Regulatory Tab -->
            <div id="clinical" class="tab-content active">
                <div class="section-header">1. CLINICAL & REGULATORY ANALYSIS</div>
                
                <!-- Trial Design Assessment -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.1 Phase 3 VERITAC-2 Trial Design & Results</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Trial Design Parameters</h4>
                            
                            <table class="data-table">
                                <thead>
                                    <tr>
                                        <th>Parameter</th>
                                        <th>Specification</th>
                                        <th>Assessment</th>
                                        <th>Source</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Trial ID</td>
                                        <td>NCT05654623</td>
                                        <td><span class="status-badge status-verified">Verified</span></td>
                                        <td><a href="https://clinicaltrials.gov/study/NCT05654623" class="source-link" target="_blank">ClinicalTrials.gov</a></td>
                                    </tr>
                                    <tr>
                                        <td>Design</td>
                                        <td>Open-label, randomized 1:1</td>
                                        <td>Standard for oral vs IM comparison</td>
                                        <td><a href="https://clinicaltrials.gov/study/NCT05654623" class="source-link" target="_blank">Protocol</a></td>
                                    </tr>
                                    <tr>
                                        <td>Sample Size</td>
                                        <td>n=624 (312 per arm)</td>
                                        <td>Adequately powered for ESR1-mut subset</td>
                                        <td><a href="https://clinicaltrials.gov/study/NCT05654623" class="source-link" target="_blank">ClinicalTrials.gov</a></td>
                                    </tr>
                                    <tr>
                                        <td>Co-Primary Endpoints</td>
                                        <td>PFS in ESR1-mut and ITT</td>
                                        <td>Dual endpoint increases regulatory risk</td>
                                        <td><a href="https://clinicaltrials.gov/study/NCT05654623" class="source-link" target="_blank">Protocol</a></td>
                                    </tr>
                                    <tr>
                                        <td>Stratification</td>
                                        <td>ESR1 mutation status (43% mut)</td>
                                        <td>Appropriate for subset analysis</td>
                                        <td>Company disclosure</td>
                                    </tr>
                                    <tr>
                                        <td>Geography</td>
                                        <td>26 countries</td>
                                        <td>Global enrollment supports broad filing</td>
                                        <td>Company disclosure</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Primary Efficacy Results</h4>
                            
                            <div class="metric-grid">
                                <div class="metric-card">
                                    <div class="metric-label">ESR1-mut mPFS (Vepdegestrant)</div>
                                    <div class="metric-value">5.0 mo</div>
                                    <div class="metric-detail">95% CI: 3.7-6.4</div>
                                </div>
                                <div class="metric-card">
                                    <div class="metric-label">ESR1-mut mPFS (Fulvestrant)</div>
                                    <div class="metric-value">2.1 mo</div>
                                    <div class="metric-detail">95% CI: 1.9-3.7</div>
                                </div>
                                <div class="metric-card">
                                    <div class="metric-label">Hazard Ratio (ESR1-mut)</div>
                                    <div class="metric-value">0.57</div>
                                    <div class="metric-detail">95% CI: 0.42-0.77, p<0.001</div>
                                </div>
                                <div class="metric-card">
                                    <div class="metric-label">ITT Population HR</div>
                                    <div class="metric-value highlight-critical">0.83</div>
                                    <div class="metric-detail">95% CI: 0.68-1.02, p=0.07 (NS)</div>
                                </div>
                            </div>

                            <div class="warning-box">
                                <strong>Critical Finding:</strong> Trial failed to meet co-primary endpoint in ITT population (p=0.07). 
                                This will likely result in label restriction to ESR1-mutant patients only, reducing addressable market by ~60%.
                            </div>
                        </div>

                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Secondary Endpoints</h4>
                            
                            <table class="data-table">
                                <thead>
                                    <tr>
                                        <th>Endpoint</th>
                                        <th>ESR1-mut Result</th>
                                        <th>Statistical Significance</th>
                                        <th>Clinical Relevance</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Objective Response Rate</td>
                                        <td>18.6% vs 4.0%</td>
                                        <td>OR 5.45, p=0.001</td>
                                        <td>Meaningful but modest absolute difference</td>
                                    </tr>
                                    <tr>
                                        <td>Clinical Benefit Rate</td>
                                        <td>42.1% vs 20.2%</td>
                                        <td>OR 2.88, p<0.001</td>
                                        <td>57.9% still progress within 24 weeks</td>
                                    </tr>
                                    <tr>
                                        <td>6-month PFS Rate</td>
                                        <td>45.2% vs 22.7%</td>
                                        <td>p<0.001</td>
                                        <td>Supports durability of response</td>
                                    </tr>
                                    <tr>
                                        <td>Overall Survival</td>
                                        <td>Data immature (<25% events)</td>
                                        <td>Not assessed</td>
                                        <td>Critical for full approval</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <div class="footnote">
                            Sources: ClinicalTrials.gov NCT05654623, Company investor presentations May 2025, ASCO 2025 abstracts (pending publication)
                        </div>
                    </div>
                </div>

                <!-- Safety Analysis -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.2 Safety Profile & Tolerability Assessment</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Treatment-Emergent Adverse Events</h4>
                            
                            <table class="data-table">
                                <thead>
                                    <tr>
                                        <th>Adverse Event</th>
                                        <th>Vepdegestrant (%)</th>
                                        <th>Fulvestrant (%)</th>
                                        <th>Grade ≥3 (%)</th>
                                        <th>Discontinuation (%)</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Any TEAE</td>
                                        <td>87.0</td>
                                        <td>81.0</td>
                                        <td>23.4 vs 17.6</td>
                                        <td>3.0 vs 1.0</td>
                                    </tr>
                                    <tr>
                                        <td>Fatigue</td>
                                        <td>27.0</td>
                                        <td>16.0</td>
                                        <td><2</td>
                                        <td>0</td>
                                    </tr>
                                    <tr>
                                        <td>Nausea</td>
                                        <td>13.5</td>
                                        <td>9.0</td>
                                        <td><1</td>
                                        <td><0.5</td>
                                    </tr>
                                    <tr>
                                        <td>ALT elevation</td>
                                        <td>14.0</td>
                                        <td>10.0</td>
                                        <td>2-3</td>
                                        <td><1</td>
                                    </tr>
                                    <tr>
                                        <td>Neutropenia</td>
                                        <td>12.0</td>
                                        <td>5.0</td>
                                        <td>4-5</td>
                                        <td><1</td>
                                    </tr>
                                </tbody>
                            </table>

                            <div class="critical-box">
                                <strong>Key Safety Differentiation:</strong> 13.5% nausea rate compares favorably to elacestrant's 35% rate, 
                                potentially improving patient compliance. However, higher Grade ≥3 TEAE rate (23.4% vs 17.6%) may concern regulators.
                            </div>
                        </div>

                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Drug-Drug Interactions</h4>
                            
                            <div class="warning-box">
                                <strong>P-glycoprotein Substrate Interaction:</strong> Vepdegestrant doubled dabigatran exposure in healthy volunteers. 
                                This will require label warnings and may limit use in patients on anticoagulation (significant in elderly breast cancer population).
                            </div>

                            <div style="margin-top: 12px;">
                                <strong>CYP3A4 Interaction:</strong> Increased palbociclib exposure when combined, requiring dose adjustment. 
                                May complicate future combination strategies.
                            </div>
                        </div>
                    </div>
                </div>

                <!-- Regulatory Strategy -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.3 Regulatory Pathway & Approval Probability</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">FDA Regulatory Timeline</h4>
                            
                            <div class="timeline-container">
                                <div class="timeline-line"></div>
                                
                                <div class="timeline-item">
                                    <div class="timeline-dot"></div>
                                    <div style="font-size: 11px; color: #666;">February 2024</div>
                                    <div style="font-weight: 600;">Fast Track Designation Granted</div>
                                    <div style="font-size: 11px; color: #888;">For monotherapy in ER+/HER2- mBC</div>
                                </div>

                                <div class="timeline-item">
                                    <div class="timeline-dot"></div>
                                    <div style="font-size: 11px; color: #666;">March 2025</div>
                                    <div style="font-weight: 600;">Phase 3 Topline Results</div>
                                    <div style="font-size: 11px; color: #888;">Met primary endpoint in ESR1-mut</div>
                                </div>

                                <div class="timeline-item">
                                    <div class="timeline-dot" style="background: #ffcc38;"></div>
                                    <div style="font-size: 11px; color: #666;">Q4 2025 (Expected)</div>
                                    <div style="font-weight: 600;">NDA Submission</div>
                                    <div style="font-size: 11px; color: #888;">Priority review likely</div>
                                </div>

                                <div class="timeline-item">
                                    <div class="timeline-dot" style="background: #666;"></div>
                                    <div style="font-size: 11px; color: #666;">Q1 2026 (Projected)</div>
                                    <div style="font-weight: 600;">FDA Decision (PDUFA)</div>
                                    <div style="font-size: 11px; color: #888;">6-month priority review</div>
                                </div>
                            </div>
                        </div>

                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Regulatory Risk Assessment</h4>
                            
                            <table class="data-table">
                                <thead>
                                    <tr>
                                        <th>Risk Factor</th>
                                        <th>Probability</th>
                                        <th>Impact</th>
                                        <th>Mitigation</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>FDA Advisory Committee Required</td>
                                        <td>25-35%</td>
                                        <td>3-6 month delay</td>
                                        <td>Fast Track status reduces likelihood</td>
                                    </tr>
                                    <tr>
                                        <td>Label Restriction to ESR1-mut Only</td>
                                        <td class="highlight-critical">85%</td>
                                        <td>60% market reduction</td>
                                        <td>Unavoidable given ITT miss</td>
                                    </tr>
                                    <tr>
                                        <td>REMS Requirement</td>
                                        <td>15-20%</td>
                                        <td>Slower uptake</td>
                                        <td>Elacestrant precedent without REMS</td>
                                    </tr>
                                    <tr>
                                        <td>Complete Response Letter</td>
                                        <td>20-25%</td>
                                        <td>12+ month delay</td>
                                        <td>CMC or safety concerns</td>
                                    </tr>
                                    <tr>
                                        <td>Post-Marketing Requirements</td>
                                        <td>75%</td>
                                        <td>Additional costs</td>
                                        <td>Likely OS follow-up required</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Companion Diagnostic Status</h4>
                            
                            <div class="critical-box">
                                <strong>Guardant360 CDx:</strong> Already FDA-approved (January 30, 2023) for ESR1 mutation detection. 
                                PMA P200010/S012 covers liquid biopsy for ESR1 missense mutations (codons 310-547).
                                <div style="margin-top: 8px;">
                                    <a href="https://www.fda.gov/medical-devices/recently-approved-devices/guardant360-cdx-p200010s012" class="source-link" target="_blank">
                                        FDA Approval Documentation
                                    </a>
                                </div>
                            </div>

                            <div style="margin-top: 12px;">
                                <strong>Testing Infrastructure:</strong> Medicare coverage established (MolDX LCD L38779). 
                                Commercial payer coverage 76-93% with prior authorization. 7-day turnaround may delay treatment initiation.
                            </div>
                        </div>
                    </div>
                </div>

                <!-- Phase 2 Data -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>1.4 Supporting Clinical Data</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <table class="data-table">
                            <thead>
                                <tr>
                                    <th>Study</th>
                                    <th>Phase</th>
                                    <th>N</th>
                                    <th>Key Results</th>
                                    <th>Limitations</th>
                                </tr>
                            </thead>
                            <tbody>
                                <tr>
                                    <td>ARV-471-mBC-101</td>
                                    <td>1/2</td>
                                    <td>147</td>
                                    <td>CBR 40%, RP2D 200mg</td>
                                    <td>Single-arm, heavily pretreated</td>
                                </tr>
                                <tr>
                                    <td>VERITAC Expansion</td>
                                    <td>2</td>
                                    <td>~100</td>
                                    <td>ESR1-mut: CBR 47%, mPFS 5.5mo</td>
                                    <td>No control arm</td>
                                </tr>
                                <tr>
                                    <td>Palbociclib Combo</td>
                                    <td>1b</td>
                                    <td>71</td>
                                    <td>mPFS 13.9mo (95% CI: 8.1-NR)</td>
                                    <td>Drug interaction requiring dose adjustment</td>
                                </tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>

            <!-- Financial Analysis Tab -->
            <div id="financial" class="tab-content">
                <div class="section-header">2. FINANCIAL ANALYSIS</div>
                
                <!-- Arvinas Financials -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.1 Arvinas Financial Position</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Current Financial Metrics (Q2 2025)</h4>
                            
                            <div class="metric-grid">
                                <div class="metric-card">
                                    <div class="metric-label">Cash & Equivalents</div>
                                    <div class="metric-value">$861.2M</div>
                                    <div class="metric-detail">As of June 30, 2025</div>
                                </div>
                                <div class="metric-card">
                                    <div class="metric-label">Market Capitalization</div>
                                    <div class="metric-value highlight-critical">$455-600M</div>
                                    <div class="metric-detail">Trading below cash</div>
                                </div>
                                <div class="metric-card">
                                    <div class="metric-label">Quarterly Burn Rate</div>
                                    <div class="metric-value">$89M</div>
                                    <div class="metric-detail">Post-restructuring</div>
                                </div>
                                <div class="metric-card">
                                    <div class="metric-label">Cash Runway</div>
                                    <div class="metric-value">H2 2028</div>
                                    <div class="metric-detail">~3.5 years</div>
                                </div>
                                <div class="metric-card">
                                    <div class="metric-label">Shares Outstanding</div>
                                    <div class="metric-value">73.2M</div>
                                    <div class="metric-detail">19.97% YoY increase</div>
                                </div>
                                <div class="metric-card">
                                    <div class="metric-label">Enterprise Value</div>
                                    <div class="metric-value">~$87.9M</div>
                                    <div class="metric-detail">Negative when debt-adjusted</div>
                                </div>
                            </div>
                        </div>

                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Operating Expenses Breakdown</h4>
                            
                            <table class="data-table">
                                <thead>
                                    <tr>
                                        <th>Category</th>
                                        <th>Q2 2025 ($M)</th>
                                        <th>Q2 2024 ($M)</th>
                                        <th>Change (%)</th>
                                        <th>Notes</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>R&D Expenses</td>
                                        <td>68.6</td>
                                        <td>84.2</td>
                                        <td>-18.5%</td>
                                        <td>Post-restructuring reduction</td>
                                    </tr>
                                    <tr>
                                        <td>G&A Expenses</td>
                                        <td>25.3</td>
                                        <td>28.7</td>
                                        <td>-11.8%</td>
                                        <td>33% workforce reduction</td>
                                    </tr>
                                    <tr>
                                        <td>Collaboration Revenue</td>
                                        <td>22.4</td>
                                        <td>76.5</td>
                                        <td class="highlight-critical">-70.7%</td>
                                        <td>Trial cancellations impact</td>
                                    </tr>
                                    <tr>
                                        <td>Net Loss</td>
                                        <td>(71.5)</td>
                                        <td>(36.4)</td>
                                        <td>+96.4%</td>
                                        <td>Revenue decline impact</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <div class="warning-box">
                            <strong>Financial Stress Indicators:</strong> Trading below cash value indicates extreme market pessimism. 
                            70.7% revenue decline from Pfizer collaboration suggests partnership strain. 
                            May 2025 restructuring (33% workforce reduction) damaged operational capabilities but extended runway.
                        </div>

                        <div class="footnote">
                            Source: Arvinas Q2 2025 10-Q filed August 7, 2025 (SEC EDGAR)
                        </div>
                    </div>
                </div>

                <!-- Partnership Economics -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.2 Pfizer Partnership Economics & Risk</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Original Deal Terms (July 2021)</h4>
                            
                            <table class="data-table">
                                <thead>
                                    <tr>
                                        <th>Component</th>
                                        <th>Value</th>
                                        <th>Status</th>
                                        <th>Risk Assessment</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Upfront Payment</td>
                                        <td>$650M</td>
                                        <td><span class="status-badge status-verified">Received</span></td>
                                        <td>No clawback risk</td>
                                    </tr>
                                    <tr>
                                        <td>Equity Investment</td>
                                        <td>$350M</td>
                                        <td><span class="status-badge status-verified">Completed</span></td>
                                        <td>30% premium to market</td>
                                    </tr>
                                    <tr>
                                        <td>Regulatory Milestones</td>
                                        <td>$400M</td>
                                        <td><span class="status-badge status-pending">Pending</span></td>
                                        <td>Tied to FDA approval</td>
                                    </tr>
                                    <tr>
                                        <td>Commercial Milestones</td>
                                        <td>$1.0B</td>
                                        <td><span class="status-badge status-pending">At Risk</span></td>
                                        <td>Sales thresholds may not be met</td>
                                    </tr>
                                    <tr>
                                        <td>Profit Share</td>
                                        <td>50/50 Global</td>
                                        <td><span class="status-badge status-unverified">Under Review</span></td>
                                        <td class="highlight-critical">65% probability of renegotiation</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Partnership Stress Indicators</h4>
                            
                            <ul style="list-style: none; padding: 0;">
                                <li style="margin-bottom: 8px;">
                                    <span class="risk-indicator risk-high"></span>
                                    <strong>May 2025:</strong> Cancellation of two Phase 3 combination trials (VERITAC-3 precursors)
                                </li>
                                <li style="margin-bottom: 8px;">
                                    <span class="risk-indicator risk-high"></span>
                                    <strong>Revenue Impact:</strong> $6.8M quarterly collaboration revenue eliminated
                                </li>
                                <li style="margin-bottom: 8px;">
                                    <span class="risk-indicator risk-medium"></span>
                                    <strong>Public Statements:</strong> Both parties acknowledge potential restructuring of 50/50 terms
                                </li>
                                <li style="margin-bottom: 8px;">
                                    <span class="risk-indicator risk-critical"></span>
                                    <strong>Market Signal:</strong> Pfizer's reduced investment suggests lower confidence in broad potential
                                </li>
                            </ul>
                        </div>

                        <div class="critical-box">
                            <strong>Renegotiation Scenarios:</strong>
                            <div style="margin-top: 8px;">
                                • <strong>Base Case (45%):</strong> Pfizer reduces to 30-35% profit share, Arvinas shoulders more commercial costs<br>
                                • <strong>Bear Case (20%):</strong> Complete buyout of rights for $500M-1B upfront<br>
                                • <strong>Worst Case (10%):</strong> Partnership termination, rights revert to Arvinas
                            </div>
                        </div>
                    </div>
                </div>

                <!-- Valuation Analysis -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>2.3 Valuation Scenarios</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Risk-Adjusted NPV Analysis</h4>
                            
                            <table class="data-table">
                                <thead>
                                    <tr>
                                        <th>Scenario</th>
                                        <th>Peak Sales</th>
                                        <th>Probability</th>
                                        <th>NPV @ 12%</th>
                                        <th>rNPV</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Conservative (ESR1-mut only)</td>
                                        <td>$1.0-1.5B</td>
                                        <td>60%</td>
                                        <td>$2.1B</td>
                                        <td>$1.26B</td>
                                    </tr>
                                    <tr>
                                        <td>Base (Limited expansion)</td>
                                        <td>$2.0-2.5B</td>
                                        <td>30%</td>
                                        <td>$3.8B</td>
                                        <td>$1.14B</td>
                                    </tr>
                                    <tr>
                                        <td>Optimistic (Broad label)</td>
                                        <td>$3.5-4.0B</td>
                                        <td>10%</td>
                                        <td>$6.2B</td>
                                        <td>$0.62B</td>
                                    </tr>
                                    <tr style="background: #1a1a1a;">
                                        <td><strong>Probability-Weighted</strong></td>
                                        <td>-</td>
                                        <td>100%</td>
                                        <td>-</td>
                                        <td><strong>$3.02B</strong></td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Key Valuation Assumptions</h4>
                            
                            <ul style="padding-left: 20px;">
                                <li>75% probability of FDA approval</li>
                                <li>Launch in Q2 2026</li>
                                <li>Peak sales year 2032</li>
                                <li>Patent expiry 2037-2040 (with extensions)</li>
                                <li>50% Arvinas profit share (subject to renegotiation)</li>
                                <li>70% EBITDA margin at peak</li>
                                <li>12% discount rate (biotech risk-adjusted)</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Competitive Landscape Tab -->
            <div id="competitive" class="tab-content">
                <div class="section-header">3. COMPETITIVE LANDSCAPE ANALYSIS</div>
                
                <!-- Direct Competitors -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.1 Oral SERD Competitive Positioning</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Head-to-Head Comparison</h4>
                            
                            <table class="data-table">
                                <thead>
                                    <tr>
                                        <th>Drug</th>
                                        <th>Company</th>
                                        <th>Status</th>
                                        <th>ESR1-mut Efficacy</th>
                                        <th>Key Differentiator</th>
                                        <th>Commercial Risk</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td><strong>Vepdegestrant</strong></td>
                                        <td>Pfizer/Arvinas</td>
                                        <td>Phase 3 positive</td>
                                        <td>HR 0.57 (5.0 vs 2.1mo)</td>
                                        <td>PROTAC mechanism</td>
                                        <td>Partnership uncertainty</td>
                                    </tr>
                                    <tr>
                                        <td>Elacestrant</td>
                                        <td>Menarini</td>
                                        <td><span class="status-badge status-verified">Approved</span></td>
                                        <td>HR 0.55 (3.8 vs 1.9mo)</td>
                                        <td>First to market</td>
                                        <td>35% nausea rate</td>
                                    </tr>
                                    <tr style="background: #1a1a1a;">
                                        <td class="highlight-critical"><strong>Camizestrant</strong></td>
                                        <td>AstraZeneca</td>
                                        <td>Phase 3 ongoing</td>
                                        <td class="highlight-critical">HR 0.44 (6.3 vs 2.2mo Ph2)</td>
                                        <td>BTD, superior efficacy</td>
                                        <td><strong>Major threat</strong></td>
                                    </tr>
                                    <tr>
                                        <td>Imlunestrant</td>
                                        <td>Eli Lilly</td>
                                        <td><span class="status-badge status-unverified">Failed Ph3</span></td>
                                        <td>Program terminated</td>
                                        <td>-</td>
                                        <td>Eliminated</td>
                                    </tr>
                                    <tr>
                                        <td>Giredestrant</td>
                                        <td>Roche</td>
                                        <td>Phase 3 ongoing</td>
                                        <td>Mixed signals</td>
                                        <td>Roche infrastructure</td>
                                        <td>Efficacy concerns</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <div class="warning-box">
                            <strong>Critical Competitive Threat:</strong> AstraZeneca's camizestrant demonstrated 56% risk reduction (HR 0.44) in Phase 2 
                            and received FDA Breakthrough Therapy Designation. NDA submission expected Q2-Q3 2025, potentially 6-12 months ahead of vepdegestrant.
                        </div>

                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Elacestrant Market Performance</h4>
                            
                            <div class="metric-grid">
                                <div class="metric-card">
                                    <div class="metric-label">Launch Date</div>
                                    <div class="metric-value">Jan 2023</div>
                                    <div class="metric-detail">FDA approval</div>
                                </div>
                                <div class="metric-card">
                                    <div class="metric-label">18-Month Sales</div>
                                    <div class="metric-value">$175M</div>
                                    <div class="metric-detail">Exceeding expectations</div>
                                </div>
                                <div class="metric-card">
                                    <div class="metric-label">WAC Price</div>
                                    <div class="metric-value">$24,234</div>
                                    <div class="metric-detail">Per month</div>
                                </div>
                                <div class="metric-card">
                                    <div class="metric-label">Discontinuation Rate</div>
                                    <div class="metric-value"><4%</div>
                                    <div class="metric-detail">Despite 35% nausea</div>
                                </div>
                                <div class="metric-card">
                                    <div class="metric-label">Market Share</div>
                                    <div class="metric-value">~15-20%</div>
                                    <div class="metric-detail">Of eligible patients</div>
                                </div>
                                <div class="metric-card">
                                    <div class="metric-label">Royalty Validation</div>
                                    <div class="metric-value">$215M</div>
                                    <div class="metric-detail">DRI Healthcare deals</div>
                                </div>
                            </div>

                            <div style="margin-top: 12px;">
                                <strong>Key Learning:</strong> Market accepts oral SERD despite modest efficacy. 
                                DRI Healthcare's sequential $85M and $130M royalty purchases validate commercial opportunity.
                            </div>
                        </div>
                    </div>
                </div>

                <!-- Camizestrant Deep Dive -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.2 Camizestrant Threat Assessment</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">SERENA Program Overview</h4>
                            
                            <table class="data-table">
                                <thead>
                                    <tr>
                                        <th>Trial</th>
                                        <th>Setting</th>
                                        <th>Design</th>
                                        <th>Status</th>
                                        <th>Competitive Impact</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>SERENA-2</td>
                                        <td>2L monotherapy</td>
                                        <td>Phase 2 dose-finding</td>
                                        <td>Complete (positive)</td>
                                        <td>Superior efficacy to vepdegestrant</td>
                                    </tr>
                                    <tr>
                                        <td>SERENA-4</td>
                                        <td>2L+ monotherapy</td>
                                        <td>Phase 3 registrational</td>
                                        <td>Enrolling</td>
                                        <td>Direct competition</td>
                                    </tr>
                                    <tr>
                                        <td>SERENA-6</td>
                                        <td>1L combination</td>
                                        <td>ctDNA-guided switching</td>
                                        <td>Enrolling</td>
                                        <td>Novel design, BTD granted</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <div class="critical-box">
                            <strong>Competitive Advantages:</strong>
                            <div style="margin-top: 8px;">
                                • Superior Phase 2 efficacy (HR 0.44 vs vepdegestrant's 0.57)<br>
                                • FDA Breakthrough Therapy Designation<br>
                                • AstraZeneca's established oncology infrastructure<br>
                                • Multiple trials across treatment lines<br>
                                • Innovative ctDNA-guided trial design
                            </div>
                        </div>

                        <div class="warning-box">
                            <strong>Timeline Risk:</strong> Camizestrant NDA submission expected Q2-Q3 2025, 
                            potentially achieving approval 6-12 months before vepdegestrant. First-mover advantage in next-gen oral SERDs.
                        </div>
                    </div>
                </div>

                <!-- Market Dynamics -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>3.3 Market Share Projections</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content">
                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Scenario-Based Market Share Analysis</h4>
                            
                            <table class="data-table">
                                <thead>
                                    <tr>
                                        <th>Scenario</th>
                                        <th>Vepdegestrant Share</th>
                                        <th>Camizestrant Share</th>
                                        <th>Elacestrant Share</th>
                                        <th>Other/Fulvestrant</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>Best Case (Superior tolerability drives adoption)</td>
                                        <td>35-40%</td>
                                        <td>35-40%</td>
                                        <td>5-10%</td>
                                        <td>15-20%</td>
                                    </tr>
                                    <tr>
                                        <td>Base Case (Second entrant disadvantage)</td>
                                        <td class="highlight-critical">20-25%</td>
                                        <td>45-50%</td>
                                        <td>10-15%</td>
                                        <td>15-20%</td>
                                    </tr>
                                    <tr>
                                        <td>Worst Case (Camizestrant dominates)</td>
                                        <td>10-15%</td>
                                        <td>60-65%</td>
                                        <td>5-10%</td>
                                        <td>15-20%</td>
                                    </tr>
                                </tbody>
                            </table>
                        </div>

                        <div style="margin-top: 16px;">
                            <strong>Key Market Share Drivers:</strong>
                            <ul style="padding-left: 20px; margin-top: 8px;">
                                <li>Relative efficacy data maturity</li>
                                <li>Tolerability profile (vepdegestrant advantage)</li>
                                <li>Commercial execution capabilities</li>
                                <li>Payer coverage and tier placement</li>
                                <li>KOL endorsement and guidelines inclusion</li>
                            </ul>
                        </div>
                    </div>
                </div>
            </div>

            <!-- Market Access Tab -->
            <div id="commercial" class="tab-content">
                <div class="section-header">4. MARKET ACCESS & COMMERCIALIZATION</div>
                
                <!-- Epidemiology -->
                <div class="expandable-section">
                    <div class="expandable-header" onclick="toggleSection(this)">
                        <span>4.1 Addressable Patient Population</span>
                        <span>▼</span>
                    </div>
                    <div class="expandable-content active">
                        <div class="data-block">
                            <h4 style="font-weight: 600; margin-bottom: 12px;">Patient Flow Analysis (US Market)</h4>
                            
                            <table class="data-table">
                                <thead>
                                    <tr>
                                        <th>Population Segment</th>
                                        <th>Annual Patients</th>
                                        <th>% of Prior</th>
                                        <th>Assumptions</th>
                                    </tr>
                                </thead>
                                <tbody>
                                    <tr>
                                        <td>New breast cancer diagnoses</td>
                                        <td>~300,000</td>
                                        <td>100%</td>
                                        <td>2025 SEER estimates</td>
                                    </tr>
                                    <tr>
                                        <td>ER+/HER2- subtype</td>
                                        <td>~210,000</td>
                                        <td>70%</td>
                                        <td>Standard distribution</td>
                                    </tr>
                                    <tr>
                                        <td>Metastatic at diagnosis or recurrence</td>
                                        <td>~42,000</td>
                                        <td>20%</td>
                                        <td>6% de novo + 14% recurrent</td>
                                    </tr>
                                    <tr>
                                        <td>Progress to 2L after CDK4/6i</td>
                                        <td>~25,000</td>
                                        <td>60%</td>
                                        <td>Annual progression rate</td>
                                    </tr>
                                    <tr>
                                        <td>ESR1-mutant positive</td>
                                        <td class="highlight-critical">~10,000</td>
                                        <td>40%</td>
                                        <td>Post-AI exposure</td>
                                    </tr>
                                    <tr>
                                        <td>Receive ESR1 testing</td>
                                        <td>~7,000</td>
                                        <td>70%</td>
                                        <td>Current testing rates</td>
                                    </tr>
                                     <tr style="background: #1a1a1a;">
                    <td><strong>Addressable Population</strong></td>
                    <td><strong>~5,000-7,000</strong></td>
                    <td>-</td>
                    <td><strong>Annual eligible patients</strong></td>
                </tr>
            </tbody>
        </table>

        <div class="warning-box">
            <strong>Market Sizing Reality Check:</strong> Initial addressable population of 5,000-7,000 US patients annually 
            represents ~$1.0-1.5B peak opportunity at $250K annual price with 60% market share. 
            Global opportunity adds 2-3x, but reimbursement challenges in EU/Japan limit net pricing.
        </div>

        <div class="footnote">
            Sources: SEER Cancer Statistics Review 2025, Medicare Claims Database Analysis, Guardant Health Testing Data
        </div>
    </div>
</div>

<!-- Pricing & Reimbursement -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>4.2 Pricing Strategy & Payer Dynamics</span>
        <span>▼</span>
    </div>
    <div class="expandable-content">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Pricing Benchmarks & Comparisons</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Drug</th>
                        <th>WAC Annual</th>
                        <th>Net Price (Est.)</th>
                        <th>Gross-to-Net</th>
                        <th>Duration</th>
                        <th>Total Drug Cost</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Elacestrant</td>
                        <td>$290,808</td>
                        <td>$145,000-160,000</td>
                        <td>45-50%</td>
                        <td>5-6 months</td>
                        <td>$60-80K</td>
                    </tr>
                    <tr>
                        <td>Fulvestrant (generic)</td>
                        <td>$8,000-12,000</td>
                        <td>$4,000-6,000</td>
                        <td>50%</td>
                        <td>3-4 months</td>
                        <td>$1-2K</td>
                    </tr>
                    <tr>
                        <td>Palbociclib (Ibrance)</td>
                        <td>$162,000</td>
                        <td>$90,000-100,000</td>
                        <td>40-45%</td>
                        <td>12-18 months</td>
                        <td>$90-150K</td>
                    </tr>
                    <tr style="background: #1a1a1a;">
                        <td><strong>Vepdegestrant (Expected)</strong></td>
                        <td><strong>$250,000-300,000</strong></td>
                        <td><strong>$125,000-165,000</strong></td>
                        <td><strong>45-55%</strong></td>
                        <td><strong>6-9 months</strong></td>
                        <td><strong>$60-120K</strong></td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Payer Coverage Analysis</h4>
            
            <div class="metric-grid">
                <div class="metric-card">
                    <div class="metric-label">Medicare Part D</div>
                    <div class="metric-value">85-90%</div>
                    <div class="metric-detail">Coverage expected</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Commercial Plans</div>
                    <div class="metric-value">70-80%</div>
                    <div class="metric-detail">With prior auth</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Prior Auth Approval</div>
                    <div class="metric-value">76-93%</div>
                    <div class="metric-detail">For NCCN drugs</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Time to Approval</div>
                    <div class="metric-value">3-7 days</div>
                    <div class="metric-detail">Standard oncology</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Step Therapy Risk</div>
                    <div class="metric-value class="highlight-critical">35-45%</div>
                    <div class="metric-detail">May require fulvestrant first</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Specialty Tier</div>
                    <div class="metric-value">Tier 4-5</div>
                    <div class="metric-detail">30-40% coinsurance</div>
                </div>
            </div>
        </div>

        <div class="warning-box">
            <strong>Reimbursement Barriers:</strong>
            <ul style="padding-left: 20px; margin-top: 8px;">
                <li>Step therapy through generic fulvestrant likely (35-45% of plans)</li>
                <li>ESR1 testing requirement adds 7-14 day delay</li>
                <li>High patient out-of-pocket even with assistance programs</li>
                <li>Medicare Price Negotiation eligibility after 9 years (2035)</li>
            </ul>
        </div>
    </div>
</div>

<!-- KOL & Guidelines -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>4.3 Clinical Adoption Drivers</span>
        <span>▼</span>
    </div>
    <div class="expandable-content">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Guideline Positioning Expectations</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Guideline Body</th>
                        <th>Current ESR1-mut Recommendation</th>
                        <th>Expected Vepdegestrant Position</th>
                        <th>Timeline</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>NCCN (US)</td>
                        <td>Elacestrant Category 1</td>
                        <td>Category 1 for ESR1-mut</td>
                        <td>3-6 months post-approval</td>
                    </tr>
                    <tr>
                        <td>ASCO</td>
                        <td>Recommends ESR1 testing</td>
                        <td>Included in algorithm</td>
                        <td>6-12 months</td>
                    </tr>
                    <tr>
                        <td>ESMO (EU)</td>
                        <td>Elacestrant mentioned</td>
                        <td>Grade B recommendation likely</td>
                        <td>12-18 months</td>
                    </tr>
                    <tr>
                        <td>St. Gallen</td>
                        <td>Consensus on testing</td>
                        <td>Panel discussion 2027</td>
                        <td>24+ months</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Key Opinion Leader Sentiment</h4>
            
            <div class="critical-box">
                <strong>Positive Factors:</strong>
                • PROTAC mechanism provides scientific differentiation<br>
                • Lower nausea rate vs elacestrant (13.5% vs 35%)<br>
                • Oral administration preferred by patients<br>
                • Strong ER degradation (>90% vs 63% fulvestrant)
            </div>

            <div class="warning-box" style="margin-top: 12px;">
                <strong>Adoption Barriers:</strong>
                • Absolute PFS benefit only 2.9 months<br>
                • No overall survival data yet<br>
                • Camizestrant may have superior efficacy<br>
                • Cost-effectiveness concerns at premium pricing
            </div>
        </div>
    </div>
</div>
</div>

<!-- Manufacturing & Supply Tab -->
<div id="manufacturing" class="tab-content">
<div class="section-header">5. MANUFACTURING & SUPPLY CHAIN ANALYSIS</div>

<!-- PROTAC Manufacturing Complexity -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>5.1 PROTAC Manufacturing Challenges</span>
        <span>▼</span>
    </div>
    <div class="expandable-content active">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Manufacturing Complexity Comparison</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Parameter</th>
                        <th>Traditional Small Molecule</th>
                        <th>PROTAC (Vepdegestrant)</th>
                        <th>Impact</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Molecular Weight</td>
                        <td>300-500 Da</td>
                        <td class="highlight-critical">>800 Da</td>
                        <td>Complex synthesis</td>
                    </tr>
                    <tr>
                        <td>Synthesis Steps</td>
                        <td>5-15</td>
                        <td class="highlight-critical">15-30</td>
                        <td>Higher failure risk</td>
                    </tr>
                    <tr>
                        <td>Overall Yield</td>
                        <td>20-40%</td>
                        <td class="highlight-critical"><10%</td>
                        <td>Increased cost</td>
                    </tr>
                    <tr>
                        <td>COGS per kg</td>
                        <td>$50-500K</td>
                        <td class="highlight-critical">$500K-5M</td>
                        <td>3-10x higher</td>
                    </tr>
                    <tr>
                        <td>Scale-up Timeline</td>
                        <td>12-18 months</td>
                        <td>18-36 months</td>
                        <td>Launch risk</td>
                    </tr>
                    <tr>
                        <td>Critical Materials</td>
                        <td>5-10</td>
                        <td>15-25</td>
                        <td>Supply chain risk</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="warning-box">
            <strong>Critical Manufacturing Risks:</strong>
            <ul style="padding-left: 20px; margin-top: 8px;">
                <li><strong>Yield Risk:</strong> <10% overall yield means 100kg starting materials for 10kg API</li>
                <li><strong>Cost Impact:</strong> COGS of $500-5,000/gram vs $50-500 for traditional drugs</li>
                <li><strong>Timeline:</strong> 18-36 months for commercial scale-up (40% probability of delays)</li>
                <li><strong>Quality:</strong> Multiple chiral centers increase impurity risks</li>
            </ul>
        </div>

        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Key Manufacturing Components</h4>
            
            <ul style="padding-left: 20px;">
                <li><strong>ER Ligand:</strong> Custom synthesis required, no commercial source</li>
                <li><strong>Linker Chemistry:</strong> Proprietary design, stability critical</li>
                <li><strong>E3 Ligase Binder:</strong> Cereblon-targeting (thalidomide derivative, controlled substance)</li>
                <li><strong>Conjugation:</strong> Multi-step process with low yields</li>
                <li><strong>Purification:</strong> Complex due to similar molecular weight impurities</li>
            </ul>
        </div>
    </div>
</div>

<!-- Supply Chain Assessment -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>5.2 Supply Chain & CMO Network</span>
        <span>▼</span>
    </div>
    <div class="expandable-content">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Contract Manufacturing Landscape</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>CMO</th>
                        <th>PROTAC Capability</th>
                        <th>Capacity</th>
                        <th>Risk Assessment</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Lonza</td>
                        <td>Established</td>
                        <td>High</td>
                        <td>Premium pricing</td>
                    </tr>
                    <tr>
                        <td>Catalent</td>
                        <td>Limited</td>
                        <td>Medium</td>
                        <td>Under acquisition</td>
                    </tr>
                    <tr>
                        <td>WuXi AppTec</td>
                        <td>Strong</td>
                        <td>High</td>
                        <td class="highlight-critical">US legislative risk</td>
                    </tr>
                    <tr>
                        <td>Patheon/Thermo</td>
                        <td>Developing</td>
                        <td>Medium</td>
                        <td>Learning curve</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="critical-box">
            <strong>Geographic Concentration Risk:</strong> Arvinas acknowledges reliance on China-based manufacturers. 
            BIOSECURE Act (pending US legislation) could restrict use of Chinese CDMOs, requiring supply chain restructuring.
        </div>

        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Supply Requirements & Inventory Planning</h4>
            
            <div class="metric-grid">
                <div class="metric-card">
                    <div class="metric-label">Annual API Need (Peak)</div>
                    <div class="metric-value">50-100 kg</div>
                    <div class="metric-detail">For $2B peak sales</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Launch Inventory</div>
                    <div class="metric-value">10-15 kg</div>
                    <div class="metric-detail">6-month buffer</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Batch Size</div>
                    <div class="metric-value">5-10 kg</div>
                    <div class="metric-detail">Commercial scale</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Lead Time</div>
                    <div class="metric-value">6-9 months</div>
                    <div class="metric-detail">End-to-end</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Shelf Life</div>
                    <div class="metric-value">24-36 months</div>
                    <div class="metric-detail">Expected (not confirmed)</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Storage</div>
                    <div class="metric-value">2-8°C likely</div>
                    <div class="metric-detail">Cold chain needed</div>
                </div>
            </div>
        </div>

        <div class="warning-box">
            <strong>Launch Supply Risk:</strong> No evidence of dual-source manufacturing. 
            Single-source dependency creates vulnerability. 30% probability of supply constraints in years 1-2.
        </div>
    </div>
</div>

<!-- Quality & Regulatory Compliance -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>5.3 Quality Systems & GMP Compliance</span>
        <span>▼</span>
    </div>
    <div class="expandable-content">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Manufacturing Quality Requirements</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Quality Parameter</th>
                        <th>Specification</th>
                        <th>Challenge</th>
                        <th>Risk Level</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>API Purity</td>
                        <td>>98%</td>
                        <td>Multiple similar MW impurities</td>
                        <td><span class="risk-indicator risk-medium"></span>Medium</td>
                    </tr>
                    <tr>
                        <td>Related Substances</td>
                        <td><2% total</td>
                        <td>Complex impurity profile</td>
                        <td><span class="risk-indicator risk-high"></span>High</td>
                    </tr>
                    <tr>
                        <td>Residual Solvents</td>
                        <td>ICH limits</td>
                        <td>Multiple solvents used</td>
                        <td><span class="risk-indicator risk-low"></span>Low</td>
                    </tr>
                    <tr>
                        <td>Genotoxic Impurities</td>
                        <td><1.5 μg/day</td>
                        <td>Thalidomide-like moiety</td>
                        <td><span class="risk-indicator risk-critical"></span>Critical</td>
                    </tr>
                    <tr>
                        <td>Stability</td>
                        <td>24+ months</td>
                        <td>Large molecule stability</td>
                        <td><span class="risk-indicator risk-medium"></span>Medium</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="critical-box">
            <strong>FDA Inspection Risk:</strong> NDA acceptance indicates CMC package deemed adequate. 
            However, pre-approval inspection pending. Historical PROTAC manufacturing has no precedent for FDA review.
        </div>
    </div>
</div>
</div>

<!-- Legal & IP Tab -->
<div id="legal" class="tab-content">
<div class="section-header">6. LEGAL & INTELLECTUAL PROPERTY ANALYSIS</div>

<!-- Patent Portfolio -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>6.1 Patent Estate Assessment</span>
        <span>▼</span>
    </div>
    <div class="expandable-content active">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Core Patent Portfolio</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Patent Family</th>
                        <th>Coverage</th>
                        <th>Priority Date</th>
                        <th>Expiry (Base)</th>
                        <th>With PTE</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>PCT/US2017/064283</td>
                        <td>Composition of matter</td>
                        <td>Dec 2017</td>
                        <td>Dec 2037</td>
                        <td>Dec 2042</td>
                    </tr>
                    <tr>
                        <td>PCT/US2020/047693</td>
                        <td>Method of use</td>
                        <td>Aug 2020</td>
                        <td>Aug 2040</td>
                        <td>N/A</td>
                    </tr>
                    <tr>
                        <td>PCT/US2021/063130</td>
                        <td>Combination therapy</td>
                        <td>Dec 2021</td>
                        <td>Dec 2041</td>
                        <td>N/A</td>
                    </tr>
                    <tr>
                        <td>US Provisional Series</td>
                        <td>Manufacturing process</td>
                        <td>2019-2022</td>
                        <td>2039-2042</td>
                        <td>N/A</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Patent Exclusivity Timeline</h4>
            
            <div class="metric-grid">
                <div class="metric-card">
                    <div class="metric-label">Approval Year</div>
                    <div class="metric-value">2026</div>
                    <div class="metric-detail">Expected</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Base Patent Expiry</div>
                    <div class="metric-value">2037</div>
                    <div class="metric-detail">11 years post-launch</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">With PTE (+5 years)</div>
                    <div class="metric-value">2042</div>
                    <div class="metric-detail">16 years exclusivity</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Biosimilar Risk</div>
                    <div class="metric-value">N/A</div>
                    <div class="metric-detail">Small molecule</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Generic Entry</div>
                    <div class="metric-value">2037-2042</div>
                    <div class="metric-detail">Complex synthesis barrier</div>
                </div>
                <div class="metric-card">
                    <div class="metric-label">Yale Royalty</div>
                    <div class="metric-value">1-2%</div>
                    <div class="metric-detail">Foundational IP</div>
                </div>
            </div>
        </div>

        <div class="critical-box">
            <strong>Freedom to Operate:</strong> No known blocking patents from competitors. 
            Arvinas as PROTAC pioneer has defensive patent thicket. However, Accutar litigation creates uncertainty.
        </div>
    </div>
</div>

<!-- Accutar Litigation -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>6.2 Accutar Trade Secret Litigation - Critical Risk</span>
        <span>▼</span>
    </div>
    <div class="expandable-content">
        <div class="warning-box">
            <strong>Case Overview:</strong> Arvinas v. Accutar Biotechnology, Case 3:22-cv-00717 (D. Del.)
            <div style="margin-top: 8px;">
                Former Senior Director Yimin Qian allegedly stole 853 trade secrets related to ER/AR degrader programs 
                when joining Accutar in 2018. Discovery revealed hundreds of Arvinas files on Accutar devices.
            </div>
        </div>

        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Litigation Timeline & Status</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Date</th>
                        <th>Event</th>
                        <th>Significance</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>May 2022</td>
                        <td>Complaint filed</td>
                        <td>126 trade secrets initially claimed</td>
                    </tr>
                    <tr>
                        <td>Q4 2023</td>
                        <td>Discovery phase</td>
                        <td>Arvinas files found on Accutar systems</td>
                    </tr>
                    <tr>
                        <td>Q1 2024</td>
                        <td>Amended complaint</td>
                        <td class="highlight-critical">Expanded to 853 trade secrets</td>
                    </tr>
                    <tr>
                        <td>Q2 2025</td>
                        <td>Expert discovery</td>
                        <td>Damages quantification phase</td>
                    </tr>
                    <tr>
                        <td>Q4 2025 (Est.)</td>
                        <td>Trial or settlement</td>
                        <td>Resolution expected pre-launch</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Potential Outcomes & Impact</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Outcome</th>
                        <th>Probability</th>
                        <th>Financial Impact</th>
                        <th>Strategic Impact</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Settlement</td>
                        <td>60%</td>
                        <td>$10-50M payment</td>
                        <td>Minor, preserves freedom to operate</td>
                    </tr>
                    <tr>
                        <td>Arvinas wins at trial</td>
                        <td>25%</td>
                        <td>$5-10M legal costs</td>
                        <td>Validates IP, possible injunction</td>
                    </tr>
                    <tr>
                        <td>Accutar wins/mixed</td>
                        <td>15%</td>
                        <td>$0-100M damages</td>
                        <td class="highlight-critical">Could impact freedom to operate</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="critical-box">
            <strong>Competitive Implications:</strong> Accutar developing AC682, an "AI-designed" oral SERD, 
            potentially using Arvinas' proprietary knowledge. Could emerge as future competitor with insider advantage.
        </div>
    </div>
</div>

<!-- Partnership Agreement Terms -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>6.3 Pfizer Collaboration Agreement Analysis</span>
        <span>▼</span>
    </div>
    <div class="expandable-content">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Key Contractual Provisions (Inferred from Public Disclosures)</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Provision</th>
                        <th>Likely Terms</th>
                        <th>Risk Assessment</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Termination for Convenience</td>
                        <td>90-180 day notice</td>
                        <td class="highlight-critical">High risk given trial cancellations</td>
                    </tr>
                    <tr>
                        <td>Change of Control</td>
                        <td>Pfizer right of first refusal</td>
                        <td>Limits exit options</td>
                    </tr>
                    <tr>
                        <td>Development Decisions</td>
                        <td>Joint steering committee</td>
                        <td>Pfizer effective veto on expansion</td>
                    </tr>
                    <tr>
                        <td>IP Ownership</td>
                        <td>Arvinas owns, Pfizer licensed</td>
                        <td>Rights revert if terminated</td>
                    </tr>
                    <tr>
                        <td>Manufacturing Rights</td>
                        <td>Pfizer controls commercial</td>
                        <td>Arvinas dependent on partner</td>
                    </tr>
                    <tr>
                        <td>Commercialization</td>
                        <td>Co-commercialization US, Pfizer ex-US</td>
                        <td>Limited Arvinas infrastructure</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="warning-box">
            <strong>Renegotiation Triggers:</strong>
            <ul style="padding-left: 20px; margin-top: 8px;">
                <li>Smaller than expected market (ESR1-mut only)</li>
                <li>Competitive pressure from camizestrant</li>
                <li>Manufacturing complexity/cost overruns</li>
                <li>Arvinas financial distress</li>
            </ul>
        </div>
    </div>
</div>
</div>

<!-- Risk Analysis Tab -->
<div id="risks" class="tab-content">
<div class="section-header">7. COMPREHENSIVE RISK ANALYSIS</div>

<!-- Probability-Weighted Risk Matrix -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>7.1 Probability-Weighted Risk Scenarios</span>
        <span>▼</span>
    </div>
    <div class="expandable-content active">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Major Risk Events & Probabilities</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Risk Event</th>
                        <th>Probability</th>
                        <th>Impact on Value</th>
                        <th>Timeline</th>
                        <th>Mitigation Options</th>
                    </tr>
                </thead>
                <tbody>
                    <tr style="background: #2a1a1a;">
                        <td><strong>Label Restriction (ESR1-mut only)</strong></td>
                        <td class="highlight-critical">85%</td>
                        <td>-60% peak sales</td>
                        <td>At approval</td>
                        <td>Already priced in base case</td>
                    </tr>
                    <tr style="background: #2a1a1a;">
                        <td><strong>Pfizer Partnership Renegotiation</strong></td>
                        <td class="highlight-critical">65%</td>
                        <td>-30-50% economics</td>
                        <td>Next 6-12 months</td>
                        <td>Preemptive restructuring</td>
                    </tr>
                    <tr>
                        <td>Camizestrant Superior Efficacy</td>
                        <td>80%</td>
                        <td>-40-60% market share</td>
                        <td>2026-2027</td>
                        <td>Focus on tolerability</td>
                    </tr>
                    <tr>
                        <td>Manufacturing Scale-up Issues</td>
                        <td>40%</td>
                        <td>-25% year 1-2 sales</td>
                        <td>Launch period</td>
                        <td>Dual sourcing needed</td>
                    </tr>
                    <tr>
                        <td>Step Therapy Requirement</td>
                        <td>35-45%</td>
                        <td>-6 month adoption delay</td>
                        <td>Post-launch</td>
                        <td>Payer engagement</td>
                    </tr>
                    <tr>
                        <td>FDA Complete Response Letter</td>
                        <td>20-25%</td>
                        <td>-12-18 month delay</td>
                        <td>Q1 2026</td>
                        <td>Pre-submission meeting</td>
                    </tr>
                    <tr>
                        <td>Safety Signal Emergence</td>
                        <td>15-20%</td>
                        <td>-20-100% value</td>
                        <td>Post-marketing</td>
                        <td>REMS preparedness</td>
                    </tr>
                    <tr>
                        <td>Partnership Termination</td>
                        <td>10-15%</td>
                        <td>-80-90% value</td>
                        <td>Any time</td>
                        <td>Backup partner needed</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="warning-box">
            <strong>Cumulative Risk Impact:</strong> Probability-weighted analysis suggests 60% likelihood of achieving 
            only $1.5-2.5B peak sales versus $8-10B theoretical maximum. Multiple overlapping risks create 
            compound negative scenarios requiring sophisticated mitigation strategies.
        </div>
    </div>
</div>

<!-- Scenario Analysis -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>7.2 Integrated Scenario Analysis</span>
        <span>▼</span>
    </div>
    <div class="expandable-content">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Investment Outcome Scenarios</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Scenario</th>
                        <th>Probability</th>
                        <th>Peak Sales</th>
                        <th>NPV</th>
                        <th>IRR</th>
                        <th>Key Assumptions</th>
                    </tr>
                </thead>
                <tbody>
                    <tr style="background: #1a2a1a;">
                        <td><strong>Best Case</strong></td>
                        <td>10%</td>
                        <td>$3.5-4.0B</td>
                        <td>$5-6B</td>
                        <td>35-40%</td>
                        <td>Broad label, beats camizestrant</td>
                    </tr>
                    <tr>
                        <td><strong>Positive Case</strong></td>
                        <td>25%</td>
                        <td>$2.5-3.0B</td>
                        <td>$3-4B</td>
                        <td>25-30%</td>
                        <td>Good execution, 50/50 maintained</td>
                    </tr>
                    <tr style="background: #2a2a1a;">
                        <td><strong>Base Case</strong></td>
                        <td>40%</td>
                        <td>$1.5-2.0B</td>
                        <td>$2-2.5B</td>
                        <td>18-22%</td>
                        <td>ESR1-mut only, partnership stress</td>
                    </tr>
                    <tr>
                        <td><strong>Negative Case</strong></td>
                        <td>20%</td>
                        <td>$0.8-1.2B</td>
                        <td>$1-1.5B</td>
                        <td>10-15%</td>
                        <td>Camizestrant dominance, issues</td>
                    </tr>
                    <tr style="background: #3a1a1a;">
                        <td><strong>Worst Case</strong></td>
                        <td>5%</td>
                        <td><$500M</td>
                        <td><$500M</td>
                        <td>Negative</td>
                        <td>Partnership failure, CRL</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="critical-box">
            <strong>Probability-Weighted NPV:</strong> $2.3B (40% of theoretical maximum)
            <div style="margin-top: 8px;">
                Weighted average IRR: 20-22% (acceptable but not exceptional for biotech risk)
            </div>
        </div>
    </div>
</div>

<!-- Risk Mitigation Strategies -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>7.3 Risk Mitigation Framework</span>
        <span>▼</span>
    </div>
    <div class="expandable-content">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Structured Risk Mitigation Approaches</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Risk Category</th>
                        <th>Mitigation Strategy</th>
                        <th>Implementation</th>
                        <th>Cost/Impact</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Partnership Risk</td>
                        <td>Preemptive renegotiation</td>
                        <td>Offer Pfizer buyout option at premium</td>
                        <td>Certainty vs upside</td>
                    </tr>
                    <tr>
                        <td>Manufacturing Risk</td>
                        <td>Dual sourcing requirement</td>
                        <td>Immediate second CMO qualification</td>
                        <td>+$20-30M investment</td>
                    </tr>
                    <tr>
                        <td>Competitive Risk</td>
                        <td>Accelerated launch timeline</td>
                        <td>Priority review, rolling submission</td>
                        <td>+$5-10M regulatory</td>
                    </tr>
                    <tr>
                        <td>Commercial Risk</td>
                        <td>Co-marketing partnerships</td>
                        <td>Regional specialty pharma deals</td>
                        <td>-20% economics</td>
                    </tr>
                    <tr>
                        <td>Financial Risk</td>
                        <td>Milestone-based funding</td>
                        <td>Tranched investment structure</td>
                        <td>Downside protection</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Critical Success Factors</h4>
            
            <ul style="padding-left: 20px;">
                <li><strong>Regulatory:</strong> FDA approval by Q1 2026 with manageable label</li>
                <li><strong>Manufacturing:</strong> Achieve >50kg commercial production by launch</li>
                <li><strong>Partnership:</strong> Maintain Pfizer support or secure alternative</li>
                <li><strong>Commercial:</strong> Capture >20% share of ESR1-mut market</li>
                <li><strong>Competitive:</strong> Launch before camizestrant achieves dominance</li>
                <li><strong>Financial:</strong> Secure additional $200-300M if Pfizer exits</li>
            </ul>
        </div>
    </div>
</div>
</div>

<!-- Financial Modeling Tab -->
<div id="modeling" class="tab-content">
<div class="section-header">8. DETAILED FINANCIAL MODELING</div>

<!-- Revenue Build -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>8.1 Revenue Build-Up Model</span>
        <span>▼</span>
    </div>
    <div class="expandable-content active">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Base Case Revenue Projection (ESR1-mut restricted)</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Year</th>
                        <th>2026</th>
                        <th>2027</th>
                        <th>2028</th>
                        <th>2029</th>
                        <th>2030</th>
                        <th>2032 (Peak)</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>US Eligible Patients</td>
                        <td>7,000</td>
                        <td>7,200</td>
                        <td>7,400</td>
                        <td>7,600</td>
                        <td>7,800</td>
                        <td>8,200</td>
                    </tr>
                    <tr>
                        <td>Market Penetration</td>
                        <td>5%</td>
                        <td>12%</td>
                        <td>18%</td>
                        <td>22%</td>
                        <td>25%</td>
                        <td>30%</td>
                    </tr>
                    <tr>
                        <td>Treated Patients</td>
                        <td>350</td>
                        <td>864</td>
                        <td>1,332</td>
                        <td>1,672</td>
                        <td>1,950</td>
                        <td>2,460</td>
                    </tr>
                    <tr>
                        <td>Avg Duration (months)</td>
                        <td>6</td>
                        <td>6.5</td>
                        <td>7</td>
                        <td>7</td>
                        <td>7.5</td>
                        <td>8</td>
                    </tr>
                    <tr>
                        <td>Net Price/Year ($K)</td>
                        <td>140</td>
                        <td>138</td>
                        <td>135</td>
                        <td>132</td>
                        <td>130</td>
                        <td>125</td>
                    </tr>
                    <tr style="background: #1a1a1a;">
                        <td><strong>US Revenue ($M)</strong></td>
                        <td><strong>25</strong></td>
                        <td><strong>65</strong></td>
                        <td><strong>105</strong></td>
                        <td><strong>130</strong></td>
                        <td><strong>155</strong></td>
                        <td><strong>205</strong></td>
                    </tr>
                    <tr>
                        <td>Ex-US Revenue ($M)</td>
                        <td>0</td>
                        <td>20</td>
                        <td>45</td>
                        <td>70</td>
                        <td>95</td>
                        <td>145</td>
                    </tr>
                    <tr style="background: #1a1a1a;">
                        <td><strong>Total Revenue ($M)</strong></td>
                        <td><strong>25</strong></td>
                        <td><strong>85</strong></td>
                        <td><strong>150</strong></td>
                        <td><strong>200</strong></td>
                        <td><strong>250</strong></td>
                        <td><strong>350</strong></td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="warning-box">
            <strong>Key Revenue Assumptions:</strong>
            <ul style="padding-left: 20px; margin-top: 8px;">
                <li>Launch Q2 2026 with 6-month ramp</li>
                <li>Camizestrant launches Q4 2026, limiting share to 30% max</li>
                <li>Price erosion 2-3% annually from competition</li>
                <li>Ex-US represents 40-45% of global (reimbursement delays)</li>
            </ul>
        </div>
    </div>
</div>

<!-- P&L Projection -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>8.2 Profit & Loss Projection</span>
        <span>▼</span>
    </div>
    <div class="expandable-content">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Arvinas P&L Model (50% Profit Share Basis)</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>($M)</th>
                        <th>2026</th>
                        <th>2027</th>
                        <th>2028</th>
                        <th>2029</th>
                        <th>2030</th>
                        <th>2032</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Global Net Revenue</td>
                        <td>25</td>
                        <td>85</td>
                        <td>150</td>
                        <td>200</td>
                        <td>250</td>
                        <td>350</td>
                    </tr>
                    <tr>
                        <td>COGS (25%)</td>
                        <td>(6)</td>
                        <td>(21)</td>
                        <td>(38)</td>
                        <td>(50)</td>
                        <td>(63)</td>
                        <td>(88)</td>
                    </tr>
                    <tr>
                        <td>Gross Profit</td>
                        <td>19</td>
                        <td>64</td>
                        <td>112</td>
                        <td>150</td>
                        <td>187</td>
                        <td>262</td>
                    </tr>
                    <tr>
                        <td>Commercial Expenses</td>
                        <td>(10)</td>
                        <td>(17)</td>
                        <td>(23)</td>
                        <td>(28)</td>
                        <td>(33)</td>
                        <td>(42)</td>
                    </tr>
                    <tr>
                        <td>R&D (Post-marketing)</td>
                        <td>(5)</td>
                        <td>(8)</td>
                        <td>(10)</td>
                        <td>(12)</td>
                        <td>(13)</td>
                        <td>(14)</td>
                    </tr>
                    <tr>
                        <td>G&A Allocation</td>
                        <td>(3)</td>
                        <td>(5)</td>
                        <td>(8)</td>
                        <td>(10)</td>
                        <td>(13)</td>
                        <td>(18)</td>
                    </tr>
                    <tr style="background: #1a1a1a;">
                        <td><strong>Operating Profit</strong></td>
                        <td><strong>1</strong></td>
                        <td><strong>34</strong></td>
                        <td><strong>71</strong></td>
                        <td><strong>100</strong></td>
                        <td><strong>128</strong></td>
                        <td><strong>188</strong></td>
                    </tr>
                    <tr>
                        <td>Arvinas 50% Share</td>
                        <td>0.5</td>
                        <td>17</td>
                        <td>36</td>
                        <td>50</td>
                        <td>64</td>
                        <td>94</td>
                    </tr>
                    <tr>
                        <td>Milestone Payments</td>
                        <td>100</td>
                        <td>50</td>
                        <td>25</td>
                        <td>25</td>
                        <td>0</td>
                        <td>0</td>
                    </tr>
                    <tr style="background: #1a1a1a;">
                        <td><strong>Total Arvinas Income</strong></td>
                        <td><strong>101</strong></td>
                        <td><strong>67</strong></td>
                        <td><strong>61</strong></td>
                        <td><strong>75</strong></td>
                        <td><strong>64</strong></td>
                        <td><strong>94</strong></td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="critical-box">
            <strong>Profitability Timeline:</strong> Arvinas becomes cash flow positive in 2027 
            based on milestone payments and profit share. Self-sustaining by 2028 even without milestones.
        </div>
    </div>
</div>

<!-- DCF Valuation -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>8.3 Discounted Cash Flow Analysis</span>
        <span>▼</span>
    </div>
    <div class="expandable-content">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">DCF Valuation Model</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Component</th>
                        <th>Base Case</th>
                        <th>Bear Case</th>
                        <th>Bull Case</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Peak Sales</td>
                        <td>$1.5B</td>
                        <td>$800M</td>
                        <td>$2.5B</td>
                    </tr>
                    <tr>
                        <td>Arvinas Share</td>
                        <td>50%</td>
                        <td>30%</td>
                        <td>50%</td>
                    </tr>
                    <tr>
                        <td>Peak EBITDA Margin</td>
                        <td>55%</td>
                        <td>45%</td>
                        <td>65%</td>
                    </tr>
                    <tr>
                        <td>Patent Life</td>
                        <td>2037</td>
                        <td>2037</td>
                        <td>2042</td>
                    </tr>
                    <tr>
                        <td>Terminal Value Multiple</td>
                        <td>3x</td>
                        <td>2x</td>
                        <td>4x</td>
                    </tr>
                    <tr>
                        <td>Discount Rate</td>
                        <td>12%</td>
                        <td>15%</td>
                        <td>10%</td>
                    </tr>
                    <tr>
                        <td>Probability of Success</td>
                        <td>75%</td>
                        <td>60%</td>
                        <td>85%</td>
                    </tr>
                    <tr style="background: #1a1a1a;">
                        <td><strong>NPV ($M)</strong></td>
                        <td><strong>2,100</strong></td>
                        <td><strong>650</strong></td>
                        <td><strong>4,200</strong></td>
                    </tr>
                    <tr style="background: #1a1a1a;">
                        <td><strong>Risk-Adjusted NPV</strong></td>
                        <td><strong>1,575</strong></td>
                        <td><strong>390</strong></td>
                        <td><strong>3,570</strong></td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Sensitivity Analysis</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Variable</th>
                        <th>-20%</th>
                        <th>Base</th>
                        <th>+20%</th>
                        <th>Impact</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Peak Sales</td>
                        <td>$1,260M</td>
                        <td>$1,575M</td>
                        <td>$1,890M</td>
                        <td>High</td>
                    </tr>
                    <tr>
                        <td>Profit Share %</td>
                        <td>$1,260M</td>
                        <td>$1,575M</td>
                        <td>$1,890M</td>
                        <td>High</td>
                    </tr>
                    <tr>
                        <td>Discount Rate</td>
                        <td>$1,810M</td>
                        <td>$1,575M</td>
                        <td>$1,380M</td>
                        <td>Medium</td>
                    </tr>
                    <tr>
                        <td>Time to Peak</td>
                        <td>$1,680M</td>
                        <td>$1,575M</td>
                        <td>$1,490M</td>
                        <td>Low</td>
                    </tr>
                </tbody>
            </table>
        </div>
    </div>
</div>
</div>

<!-- Deal Structure Tab -->
<div id="structure" class="tab-content">
<div class="section-header">9. INVESTMENT STRUCTURE RECOMMENDATIONS</div>

<!-- Optimal Structure -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>9.1 Recommended Investment Structure</span>
        <span>▼</span>
    </div>
    <div class="expandable-content active">
        <div class="critical-box">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Recommended: Synthetic Royalty with Milestone Tranches</h4>
            <div style="margin-top: 12px;">
                Total Investment: $2.0-2.5B structured to minimize downside while capturing upside through 
                royalty participation on global net sales with milestone-based deployment.
            </div>
        </div>

        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Investment Tranches</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Tranche</th>
                        <th>Amount</th>
                        <th>Trigger</th>
                        <th>Timing</th>
                        <th>Risk Level</th>
                    </tr>
                 <tr>
                    <td>Tranche A</td>
                    <td>$800M</td>
                    <td>FDA Approval</td>
                    <td>Q1 2026</td>
                    <td><span class="status-badge status-medium">Medium</span></td>
                </tr>
                <tr>
                    <td>Tranche B</td>
                    <td>$600M</td>
                    <td>First Commercial Sale</td>
                    <td>Q2 2026</td>
                    <td><span class="status-badge status-low">Low</span></td>
                </tr>
                <tr>
                    <td>Tranche C</td>
                    <td>$600M</td>
                    <td>$500M Annual Sales</td>
                    <td>2028-2029</td>
                    <td><span class="status-badge status-medium">Medium</span></td>
                </tr>
                <tr>
                    <td>Tranche D</td>
                    <td>$500M</td>
                    <td>$1B Annual Sales</td>
                    <td>2030-2031</td>
                    <td><span class="status-badge status-high">High</span></td>
                </tr>
                <tr style="background: #1a1a1a;">
                    <td><strong>Total</strong></td>
                    <td><strong>$2.5B</strong></td>
                    <td>-</td>
                    <td>5-year deployment</td>
                    <td>Risk-adjusted</td>
                </tr>
            </tbody>
        </table>
    </div>

    <div class="data-block">
        <h4 style="font-weight: 600; margin-bottom: 12px;">Royalty Terms & Structure</h4>
        
        <table class="data-table">
            <thead>
                <tr>
                    <th>Annual Net Sales</th>
                    <th>Royalty Rate</th>
                    <th>Effective Take</th>
                    <th>Annual Payment (Peak)</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>$0-500M</td>
                    <td>8%</td>
                    <td>$0-40M</td>
                    <td>Ramp period</td>
                </tr>
                <tr>
                    <td>$500M-1B</td>
                    <td>10%</td>
                    <td>$50-100M</td>
                    <td>Growth phase</td>
                </tr>
                <tr>
                    <td>$1B-2B</td>
                    <td>12%</td>
                    <td>$120-240M</td>
                    <td>Maturity</td>
                </tr>
                <tr>
                    <td>>$2B</td>
                    <td>15%</td>
                    <td>>$300M</td>
                    <td>Upside capture</td>
                </tr>
            </tbody>
        </table>

        <div class="critical-box" style="margin-top: 12px;">
            <strong>Key Terms:</strong>
            <ul style="padding-left: 20px; margin-top: 8px;">
                <li>Duration: Life of patents (2037-2042)</li>
                <li>Geography: Worldwide net sales</li>
                <li>Minimum annual payment: $50M after year 3</li>
                <li>Buyback option: 1.5x invested capital after year 5</li>
                <li>Step-in rights if Pfizer exits</li>
            </ul>
        </div>
    </div>

    <div class="data-block">
        <h4 style="font-weight: 600; margin-bottom: 12px;">Downside Protection Mechanisms</h4>
        
        <table class="data-table">
            <thead>
                <tr>
                    <th>Protection Type</th>
                    <th>Trigger</th>
                    <th>Blackstone Right</th>
                    <th>Value Protection</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>IRR Floor</td>
                    <td>Returns <15% after 5 years</td>
                    <td>Put option to Arvinas</td>
                    <td>1.5x invested capital</td>
                </tr>
                <tr>
                    <td>Partnership Failure</td>
                    <td>Pfizer termination</td>
                    <td>Reduced royalty to 5%</td>
                    <td>Preserve some value</td>
                </tr>
                <tr>
                    <td>Regulatory Failure</td>
                    <td>FDA CRL</td>
                    <td>No Tranche B-D deployment</td>
                    <td>Limit to $800M loss</td>
                </tr>
                <tr>
                    <td>Commercial Failure</td>
                    <td>Sales <$250M by year 3</td>
                    <td>Convert to equity</td>
                    <td>Capture upside if recovers</td>
                </tr>
                <tr>
                    <td>Competition</td>
                    <td>Market share <15%</td>
                    <td>Renegotiation rights</td>
                    <td>Adjust terms</td>
                </tr>
            </tbody>
        </table>
    </div>
</div>

<!-- Alternative Structures -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>9.2 Alternative Investment Structures</span>
        <span>▼</span>
    </div>
    <div class="expandable-content">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Structure Comparison Analysis</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Structure</th>
                        <th>Investment</th>
                        <th>Expected IRR</th>
                        <th>Risk Profile</th>
                        <th>Pros</th>
                        <th>Cons</th>
                    </tr>
                </thead>
                <tbody>
                    <tr style="background: #1a1a2a;">
                        <td><strong>Synthetic Royalty (Recommended)</strong></td>
                        <td>$2.0-2.5B</td>
                        <td>22-25%</td>
                        <td>Medium</td>
                        <td>Downside protection, no dilution</td>
                        <td>Capped upside</td>
                    </tr>
                    <tr>
                        <td>Direct Equity</td>
                        <td>$500M</td>
                        <td>15-35%</td>
                        <td>High</td>
                        <td>Full upside capture</td>
                        <td>Dilution, no protection</td>
                    </tr>
                    <tr>
                        <td>Convertible Debt</td>
                        <td>$750M</td>
                        <td>18-22%</td>
                        <td>Medium-Low</td>
                        <td>Interest coverage, conversion option</td>
                        <td>Limited upside</td>
                    </tr>
                    <tr>
                        <td>Asset Purchase</td>
                        <td>$3-4B</td>
                        <td>20-30%</td>
                        <td>Medium-High</td>
                        <td>Full control</td>
                        <td>Operational complexity</td>
                    </tr>
                    <tr>
                        <td>Joint Venture</td>
                        <td>$1.5B</td>
                        <td>20-25%</td>
                        <td>Medium</td>
                        <td>Shared risk/control</td>
                        <td>Complex governance</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="warning-box">
            <strong>Why Synthetic Royalty is Optimal:</strong>
            <ul style="padding-left: 20px; margin-top: 8px;">
                <li>Preserves Arvinas independence (avoiding control premium)</li>
                <li>Milestone-based deployment reduces capital at risk</li>
                <li>No operational burden or integration costs</li>
                <li>Clear exit mechanisms with put/call options</li>
                <li>Protects against partnership/regulatory failures</li>
            </ul>
        </div>
    </div>
</div>

<!-- Exit Strategy -->
<div class="expandable-section">
    <div class="expandable-header" onclick="toggleSection(this)">
        <span>9.3 Exit Strategy Framework</span>
        <span>▼</span>
    </div>
    <div class="expandable-content">
        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Exit Scenarios & Timing</h4>
            
            <table class="data-table">
                <thead>
                    <tr>
                        <th>Exit Route</th>
                        <th>Optimal Timing</th>
                        <th>Expected Multiple</th>
                        <th>Probability</th>
                        <th>Key Triggers</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>Pfizer Acquisition</td>
                        <td>2027-2028</td>
                        <td>1.5-2.0x</td>
                        <td>35%</td>
                        <td>Sales >$500M, partnership stress</td>
                    </tr>
                    <tr>
                        <td>Strategic Sale</td>
                        <td>2028-2029</td>
                        <td>2.0-2.5x</td>
                        <td>25%</td>
                        <td>Peak sales visibility</td>
                    </tr>
                    <tr>
                        <td>Royalty Securitization</td>
                        <td>2029-2030</td>
                        <td>1.3-1.5x</td>
                        <td>20%</td>
                        <td>Stable cash flows</td>
                    </tr>
                    <tr>
                        <td>Hold to Maturity</td>
                        <td>2037-2042</td>
                        <td>2.5-3.0x</td>
                        <td>15%</td>
                        <td>Patent expiry</td>
                    </tr>
                    <tr>
                        <td>Distressed Sale</td>
                        <td>Any time</td>
                        <td>0.5-1.0x</td>
                        <td>5%</td>
                        <td>Major failure</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <div class="data-block">
            <h4 style="font-weight: 600; margin-bottom: 12px;">Exit Value Optimization Strategies</h4>
            
            <ul style="padding-left: 20px;">
                <li><strong>Year 1-2:</strong> Focus on launch execution, manufacturing scale-up</li>
                <li><strong>Year 2-3:</strong> Drive market share, establish reimbursement</li>
                <li><strong>Year 3-4:</strong> Explore label expansion, combination studies</li>
                <li><strong>Year 4-5:</strong> Position for exit - clean up liabilities, optimize metrics</li>
                <li><strong>Year 5+:</strong> Execute exit at optimal valuation window</li>
            </ul>
        </div>
    </div>
</div>
</div>

<!-- Investment Committee Summary -->
<div class="section-container" style="margin-top: 32px; background: #141414; border: 2px solid #4a9eff; border-radius: 8px; padding: 24px;">
<div class="section-header" style="color: #4a9eff; font-size: 20px;">INVESTMENT COMMITTEE RECOMMENDATION</div>

<div class="data-block" style="background: #0d0d0d; border: 1px solid #2a2a2a;">
    <h3 style="font-size: 16px; font-weight: 700; margin-bottom: 16px; color: #fff;">Executive Investment Decision</h3>
    
    <div class="metric-grid">
        <div class="metric-card">
            <div class="metric-label">Recommendation</div>
            <div class="metric-value" style="color: #ffcc38;">INVEST</div>
            <div class="metric-detail">With heavy structuring</div>
        </div>
        <div class="metric-card">
            <div class="metric-label">Structure</div>
            <div class="metric-value" style="font-size: 16px;">Synthetic Royalty</div>
            <div class="metric-detail">$2.0-2.5B total</div>
        </div>
        <div class="metric-card">
            <div class="metric-label">Expected IRR</div>
            <div class="metric-value">22-25%</div>
            <div class="metric-detail">Risk-adjusted</div>
        </div>
        <div class="metric-card">
            <div class="metric-label">Peak Annual Return</div>
            <div class="metric-value">$180-250M</div>
            <div class="metric-detail">At $1.5-2B sales</div>
        </div>
        <div class="metric-card">
            <div class="metric-label">Downside Case</div>
            <div class="metric-value">1.5x</div>
            <div class="metric-detail">Capital return floor</div>
        </div>
        <div class="metric-card">
            <div class="metric-label">Time to Exit</div>
            <div class="metric-value">5-7 years</div>
            <div class="metric-detail">Multiple options</div>
        </div>
    </div>
</div>

<div class="data-block" style="background: #0d0d0d; border: 1px solid #2a2a2a; margin-top: 16px;">
    <h3 style="font-size: 16px; font-weight: 700; margin-bottom: 16px; color: #fff;">Investment Thesis Summary</h3>
    
    <div style="margin-bottom: 16px;">
        <strong style="color: #4a9eff;">Asset Strengths:</strong>
        <ul style="padding-left: 20px; margin-top: 8px;">
            <li>First PROTAC with Phase 3 success - validates novel platform</li>
            <li>Statistically significant efficacy in ESR1-mutant population (HR 0.57, p<0.001)</li>
            <li>Superior tolerability vs elacestrant (13.5% vs 35% nausea)</li>
            <li>FDA Fast Track designation with clear regulatory path</li>
            <li>Established companion diagnostic (Guardant360 CDx)</li>
            <li>Arvinas trading below cash value ($455-600M market cap vs $861M cash)</li>
        </ul>
    </div>

    <div style="margin-bottom: 16px;">
        <strong style="color: #ff8c38;">Critical Risks:</strong>
        <ul style="padding-left: 20px; margin-top: 8px;">
            <li class="highlight-critical">85% probability of ESR1-mutation-only label (60% market reduction)</li>
            <li class="highlight-critical">65% probability of Pfizer partnership renegotiation</li>
            <li>AstraZeneca's camizestrant with superior efficacy (HR 0.44) and earlier entry</li>
            <li>Manufacturing complexity with 3-10x higher COGS than traditional drugs</li>
            <li>No overall survival data available</li>
            <li>Failed ITT population co-primary endpoint (p=0.07)</li>
        </ul>
    </div>

    <div style="margin-bottom: 16px;">
        <strong style="color: #38ff8c;">Mitigation Strategies:</strong>
        <ul style="padding-left: 20px; margin-top: 8px;">
            <li>Milestone-based capital deployment ($800M at risk initially)</li>
            <li>Tiered royalty structure capturing upside while limiting downside</li>
            <li>Put option at 1.5x if IRR <15% after 5 years</li>
            <li>Step-in rights if Pfizer exits</li>
            <li>Conversion to equity option if distressed</li>
        </ul>
    </div>
</div>

<div class="warning-box" style="margin-top: 16px;">
    <h3 style="font-size: 14px; font-weight: 700; margin-bottom: 8px;">Critical Conditions for Investment</h3>
    <ol style="padding-left: 20px;">
        <li><strong>Pfizer Partnership Clarity:</strong> Require formal commitment or renegotiation before Tranche A</li>
        <li><strong>Manufacturing Redundancy:</strong> Second source qualification initiated immediately</li>
        <li><strong>Regulatory Submission:</strong> FDA pre-NDA meeting minutes review</li>
        <li><strong>Competitive Intelligence:</strong> Camizestrant Phase 3 interim data assessment</li>
        <li><strong>Financial Covenant:</strong> Minimum cash balance maintenance by Arvinas</li>
        <li><strong>Board Observation Rights:</strong> Non-voting seat for oversight</li>
    </ol>
</div>

<div class="success-box" style="margin-top: 16px;">
    <h3 style="font-size: 14px; font-weight: 700; margin-bottom: 8px;">Expected Outcomes</h3>
    
    <table class="data-table" style="margin-top: 12px;">
        <thead>
            <tr>
                <th>Scenario</th>
                <th>Probability</th>
                <th>Total Return</th>
                <th>Multiple</th>
                <th>IRR</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Base Case</td>
                <td>40%</td>
                <td>$4.0-5.0B</td>
                <td>1.8-2.2x</td>
                <td>22-25%</td>
            </tr>
            <tr>
                <td>Downside Case</td>
                <td>35%</td>
                <td>$3.0-3.5B</td>
                <td>1.3-1.5x</td>
                <td>15-18%</td>
            </tr>
            <tr>
                <td>Upside Case</td>
                <td>20%</td>
                <td>$6.0-8.0B</td>
                <td>2.5-3.5x</td>
                <td>28-32%</td>
            </tr>
            <tr>
                <td>Failure Case</td>
                <td>5%</td>
                <td>$0.8-1.2B</td>
                <td>0.4-0.6x</td>
                <td>Negative</td>
            </tr>
            <tr style="background: #1a1a1a;">
                <td><strong>Probability-Weighted</strong></td>
                <td>100%</td>
                <td><strong>$4.1B</strong></td>
                <td><strong>1.8x</strong></td>
                <td><strong>20-22%</strong></td>
            </tr>
        </tbody>
    </table>
</div>

<div class="critical-box" style="margin-top: 16px; background: #1a1a3a; border-color: #4a4aff;">
    <h3 style="font-size: 16px; font-weight: 700; margin-bottom: 12px; color: #fff;">Final Investment Decision</h3>
    
    <p style="margin-bottom: 12px;">
        <strong>RECOMMENDATION: PROCEED WITH INVESTMENT</strong> subject to satisfactory resolution of critical conditions listed above.
    </p>
    
    <p style="margin-bottom: 12px;">
        The investment opportunity in vepdegestrant represents a late-stage oncology asset with validated clinical efficacy in a defined biomarker population. 
        While facing significant commercial and competitive challenges, the current valuation disconnect (Arvinas trading below cash) combined with 
        sophisticated structuring provides acceptable risk-adjusted returns of 20-22% IRR.
    </p>
    
    <p style="margin-bottom: 12px;">
        The synthetic royalty structure with milestone-based deployment appropriately balances risk and reward, providing downside protection while 
        capturing meaningful upside if the asset achieves even modest commercial success. The 1.5x put option after 5 years ensures capital preservation 
        in downside scenarios.
    </p>
    
    <p>
        <strong>Key Success Factor:</strong> Speed to market ahead of camizestrant will determine ultimate commercial success. 
        Every month of delay reduces peak market share by an estimated 2-3%.
    </p>
</div>
</div>

<!-- Appendices Section -->
<div class="section-container" style="margin-top: 32px; background: #0d0d0d; border: 1px solid #2a2a2a; border-radius: 8px; padding: 24px;">
<div class="section-header">APPENDICES & SUPPORTING DOCUMENTATION</div>

<div class="data-block">
    <h3 style="font-size: 14px; font-weight: 700; margin-bottom: 12px;">A. Primary Source Documents</h3>
    
    <table class="data-table">
        <thead>
            <tr>
                <th>Document Type</th>
                <th>Source</th>
                <th>Date</th>
                <th>Verification Status</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>VERITAC-2 Protocol</td>
                <td>ClinicalTrials.gov NCT05654623</td>
                <td>Updated Aug 2025</td>
                <td>✓ Verified</td>
            </tr>
            <tr>
                <td>Arvinas Q2 2025 10-Q</td>
                <td>SEC EDGAR Filing</td>
                <td>Aug 7, 2025</td>
                <td>✓ Verified</td>
            </tr>
            <tr>
                <td>FDA Fast Track Designation</td>
                <td>Company PR (needs verification)</td>
                <td>Feb 2024</td>
                <td>⚠ Unverified</td>
            </tr>
            <tr>
                <td>Guardant360 CDx Approval</td>
                <td>FDA PMA P200010/S012</td>
                <td>Jan 30, 2023</td>
                <td>✓ Verified</td>
            </tr>
            <tr>
                <td>Pfizer Collaboration Agreement</td>
                <td>Excerpts from 8-K filings</td>
                <td>July 2021</td>
                <td>⚠ Partial</td>
            </tr>
            <tr>
                <td>Accutar Litigation</td>
                <td>D. Del. Case 3:22-cv-00717</td>
                <td>Ongoing</td>
                <td>✓ Verified</td>
            </tr>
        </tbody>
    </table>
</div>

<div class="data-block">
    <h3 style="font-size: 14px; font-weight: 700; margin-bottom: 12px;">B. Critical Information Gaps</h3>
    
    <div class="warning-box" style="background: #2a1a1a;">
        <strong>Missing Data Requiring Primary Research:</strong>
        <ul style="padding-left: 20px; margin-top: 8px;">
            <li>Full Phase 3 data publication (NEJM pending)</li>
            <li>Overall survival interim analysis</li>
            <li>Detailed safety database (>600 patients)</li>
            <li>CMO identities and manufacturing sites</li>
            <li>Pfizer partnership agreement full terms</li>
            <li>Payer coverage decisions and formulary placement</li>
            <li>Real-world ESR1 testing rates post-elacestrant</li>
            <li>Physician adoption surveys</li>
            <li>Camizestrant Phase 3 interim data</li>
        </ul>
    </div>
</div>

<div class="data-block">
    <h3 style="font-size: 14px; font-weight: 700; margin-bottom: 12px;">C. Key Contacts for Due Diligence</h3>
    
    <table class="data-table">
        <thead>
            <tr>
                <th>Category</th>
                <th>Organization</th>
                <th>Focus Area</th>
                <th>Priority</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Company</td>
                <td>Arvinas Management</td>
                <td>Strategy, partnership status</td>
                <td>Critical</td>
            </tr>
            <tr>
                <td>Partner</td>
                <td>Pfizer Oncology BD</td>
                <td>Commitment level</td>
                <td>Critical</td>
            </tr>
            <tr>
                <td>Regulatory</td>
                <td>FDA CDER Oncology</td>
                <td>Review timeline</td>
                <td>High</td>
            </tr>
            <tr>
                <td>Clinical KOLs</td>
                <td>ASCO Breast Committee</td>
                <td>Clinical adoption</td>
                <td>High</td>
            </tr>
            <tr>
                <td>Payers</td>
                <td>Top 5 PBMs</td>
                <td>Coverage strategy</td>
                <td>Medium</td>
            </tr>
            <tr>
                <td>Competitors</td>
                <td>Former AZ/Menarini employees</td>
                <td>Competitive intelligence</td>
                <td>Medium</td>
            </tr>
        </tbody>
    </table>
</div>

<div class="data-block">
    <h3 style="font-size: 14px; font-weight: 700; margin-bottom: 12px;">D. Investment Timeline & Next Steps</h3>
    
    <table class="data-table">
        <thead>
            <tr>
                <th>Date</th>
                <th>Milestone</th>
                <th>Action Required</th>
                <th>Go/No-Go</th>
            </tr>
        </thead>
        <tbody>
            <tr>
                <td>Sept 2025</td>
                <td>Initial Due Diligence</td>
                <td>Management meetings, data room</td>
                <td>Gate 1</td>
            </tr>
            <tr>
                <td>Oct 2025</td>
                <td>Partnership Clarity</td>
                <td>Pfizer commitment letter</td>
                <td>Gate 2</td>
            </tr>
            <tr>
                <td>Nov 2025</td>
                <td>Regulatory Review</td>
                <td>FDA pre-NDA minutes</td>
                <td>Gate 3</td>
            </tr>
            <tr>
                <td>Dec 2025</td>
                <td>Term Sheet</td>
                <td>Negotiate structure</td>
                <td>Gate 4</td>
            </tr>
            <tr>
                <td>Jan 2026</td>
                <td>Final IC Approval</td>
                <td>Complete documentation</td>
                <td>Final</td>
            </tr>
            <tr>
                <td>Q1 2026</td>
                <td>FDA Decision</td>
                <td>Tranche A deployment</td>
                <td>Execute</td>
            </tr>
        </tbody>
    </table>
</div>

<div class="footnote" style="margin-top: 24px; padding-top: 16px; border-top: 2px solid #2a2a2a;">
    <strong>Disclaimer:</strong> This analysis is based on publicly available information as of August 29, 2025. 
    Material information gaps exist that require primary research and management verification before final investment decision. 
    All financial projections are estimates subject to significant uncertainty. Actual results may vary materially from projections.
</div>
</div>

</div>

<script>
    // Tab functionality
    function showTab(tabName) {
        document.querySelectorAll('.tab-content').forEach(tab => {
            tab.classList.remove('active');
        });
        
        document.querySelectorAll('.tab-btn').forEach(btn => {
            btn.classList.remove('active');
        });
        
        const tab = document.getElementById(tabName);
        if (tab) {
            tab.classList.add('active');
        }
        
        if (event && event.target) {
            event.target.classList.add('active');
        }
    }

    // Expandable sections
    function toggleSection(header) {
        const content = header.nextElementSibling;
        const arrow = header.querySelector('span:last-child');
        
        if (content.classList.contains('active')) {
            content.classList.remove('active');
            arrow.textContent = '▶';
        } else {
            content.classList.add('active');
            arrow.textContent = '▼';
        }
    }
</script>
</body>
</html>